Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns

Trends in Endocrinology and Metabolism : TEM
Soo LimMichael Nauck

Abstract

Several new glucose-lowering medications have been approved, such as dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs), and sodium glucose cotransporter-2 inhibitors. Among GLP-1RAs, lixisenatide, a short-acting drug, did not show cardiovascular (CV) benefits in patients with Type 2 diabetes mellitus (T2D) and acute coronary syndrome. Extended-release exenatide was also not significantly better for CV outcomes. By contrast, once daily liraglutide and once weekly semaglutide, both long-acting GLP-1RAs, decreased the incidence of major adverse CV events and mortality. This Review attempts to explain favorable CV results with some, but not all, GLP-1RAs, to aid in their differential prescription with the aim of further reducing the adverse CV burden of T2D.

Citations

May 19, 2018·Nature Reviews. Endocrinology·Sudesna Chatterjee, Melanie J Davies
May 14, 2019·Current Medical Research and Opinion·Manel Mata-CasesDídac Mauricio
Jun 5, 2019·Journal of Stroke·Chang Ho Ahn, Soo Lim
Oct 9, 2019·Journal of Microencapsulation·Luis Peña IcartLuís Maurício T R Lima
Jun 17, 2020·Journal of Obesity & Metabolic Syndrome·Soo LimBo Kyung Koo
Nov 18, 2018·Nature Reviews. Endocrinology·Christoffer ClemmensenSusanna M Hofmann
Jul 1, 2020·Herz·Dirk Müller-WielandNikolaus Marx
Jul 25, 2019·Nature Reviews. Endocrinology·Clifford J Bailey
Jul 28, 2020·International Journal of Obesity Supplements·Mauro CataldiUNKNOWN Obesity Programs of nutrition, Education, Research and Assessment (OPERA) Group
Jul 3, 2018·Journal of Atherosclerosis and Thrombosis·Hiroyuki TakahashiToshihiko Yanase
Dec 16, 2020·Critical Reviews in Food Science and Nutrition·Caleb AcquahDominic Agyei
Nov 15, 2020·Nature Reviews. Endocrinology·Soo LimMichael A Nauck
Jan 22, 2021·International Journal of Obesity : Journal of the International Association for the Study of Obesity·Jung Ha ParkSoo Lim
Jun 14, 2021·Metabolism: Clinical and Experimental·Raymond PranataIan Huang
Jul 25, 2021·International Journal of Molecular Sciences·Weronika BielkaAndrzej Pawlik
Nov 11, 2020·Current Pharmaceutical Design·Gerasimos SiasosDimitrios Tousoulis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.